Psychiatry
Asenapine
Brand: Saphris®
PBAC's latest decision on Asenapine: Recommended with restriction (2011). Considered for treatment of schizophrenia in adults.
PBAC outcome
Recommended with restriction
Authority Required (STREAMLINED)
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
2
2011 → 2011
Eligible population
adults with schizophrenia
- Therapy area
- Psychiatry
- Line of therapy
- Any
- Evidence base
- RCT
- Primary endpoint
- PANSS total score
- Key trials
- Trials 41021, 41022, 25517, 25543, 41512, 25520, 25544, 41004, 41500
- Comparator
- risperidone
- Economic model
- Cost-minimisation
- ICER note
- Cost minimisation analysis performed; no ICER calculated
Submission history
- Jul 2011: Recommended with restriction · Authority Required
- Jul 2011: Recommended with restriction · Authority Required (STREAMLINED)
Open on full dashboard →